Zontivity approved for people at high-risk of heart attack, stroke

(HealthDay)—Zontivity (vorapaxar) tablets have been approved by the U.S. and Drug Administration for people at high risk of heart attack or stroke.

The drug is the first in a new class called protease-activated receptor-1 antagonists, designed to weaken the tendency of platelets to clump and form a blood clot. But the agency said the drug increases users' risks of developing life-threatening bleeding. Zontivity's label includes a boxed warning describing this risk, the FDA said Thursday in a news release.

The drug is meant for people who have had a previous or blocked arteries in the arms or legs. It should not be used by people who have had a prior stroke, "mini-" or a prior episode of bleeding in the head, the agency warned.

The most common side effects include bleeding and bruising. Users who have these side effects should report them immediately to their doctors, the FDA advised.

Zontivity is made by Merck Sharp and Dohme Corp., whose parent Merck & Co. is based in Whitehouse Station, N.J.

More information: Visit the FDA to learn more.

add to favorites email to friend print save as pdf

Related Stories

Daily aspirin regimen not safe for everyone, FDA warns

May 06, 2014

(HealthDay)—Taking an aspirin a day can help prevent heart attack and stroke in people who have suffered such health crises in the past, but not in people who have never had heart problems, according to ...

Merck blood thinner shows mixed results: study

Mar 24, 2012

An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers said Saturday.

Kcentra approved to stop severe bleeding in heart patients

Apr 30, 2013

(HealthDay)—Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and ...

Northera approved for rare blood pressure condition

Feb 19, 2014

(HealthDay)—Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Merck: New drugs pending approval or in late tests

May 06, 2014

Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others, company executives said Tuesday during a briefing on Merck's business.

Recommended for you

Added benefit of vedolizumab is not proven

36 minutes ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments